Biomerica, Inc

Biomerica manufactures primarily in the United States and Mexico, with Biomerica de Mexico operating as a significant manufacturing facility. The company also has BioEurope GmbH and a sales presence in Germany supporting Europe and South America, while management notes relationships across Europe, Eastern Europe, the Middle East, Latin America, Canada, and the United States. A significant portion of revenue is derived from international sales, and the company specifically cites distributors in Europe, China, and other countries as important markets. This geographic mix creates both growth opportunities and operational exposure to currency, regulatory, and cross-border supply chain risk. The company also sources certain raw materials from Asia and other regions, which adds procurement and logistics complexity.

Biomerica faces substantial going-concern and financing risk because it has a history of operating losses, negative operating cash flow, and limited cash resources relative to its operating needs. The company also depends on successful commercialization of new products and international expansion, which may not scale quickly enough to offset cash burn. Its business is exposed to regulatory and certification risk because sales in Europe, China, and other markets require compliance with changing quality and IVDR requirements; failure could disrupt sales or force product withdrawals. Manufacturing in Mexico and sourcing raw materials from Asia create supply-chain, labor, currency, and geopolitical exposure, while customer concentration can make quarterly results volatile when a small number of buyers account for a large share of sales or receivables. As a diagnostics company, it also faces typical industry risks around product performance, reimbursement, distributor dependence, and inventory obsolescence.